The New Jersey-based Slayback Pharma LLC has announced the closing of a $60m financing by the private equity firm KKR, putting the spotlight on investment and mergers and acquisition (M&A) appetite in the specialty space, especially injectables.
Slayback’s ‘Thoughtful’ Generics Play Nets $60m KKR Investment
Niche plays continue to attract deal interest, with the global investment firm KKR pumping in $60m in the complex generic and specialty products firm Slayback Pharma, headed by a former executive of India’s Dr Reddy’s Laboratories.